239 related articles for article (PubMed ID: 37137825)
1. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
2. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
[No Abstract] [Full Text] [Related]
3. Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study.
Chen H; Fu JJ; Li L; Wang X; Pan XC
J Gastroenterol Hepatol; 2024 Jan; 39(1):180-184. PubMed ID: 37718592
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
5. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
[TBL] [Abstract][Full Text] [Related]
6. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
[No Abstract] [Full Text] [Related]
10. [Study on early predictive factors of an incomplete viral response with 48 week-entecavir therapy in HBeAg-positive chronic hepatitis B patients].
Zhou ZF; Ding Y; Zhang C; Fan YX; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1008-1012. PubMed ID: 34865347
[No Abstract] [Full Text] [Related]
11. Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia.
Sanai FM; Aljawad M; Alghamdi AS; Yehoshua A; Khathlan A; Alghamdi M; Kozma S; Smith N; El-Moustaid F; Jeyakumar S; Kachru N
Saudi J Gastroenterol; 2024 Jan; 30(1):23-29. PubMed ID: 37417192
[TBL] [Abstract][Full Text] [Related]
12. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S; Tamaki N; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Izumi N
JGH Open; 2023 Aug; 7(8):567-571. PubMed ID: 37649865
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
[No Abstract] [Full Text] [Related]
15. [Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B].
Chang CD; Dong C; Zhao SX; Yuan XW; Zhang XX; Zhao DD; Dou Y; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):855-861. PubMed ID: 37723068
[No Abstract] [Full Text] [Related]
16. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Kim YJ; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
World J Gastroenterol; 2012 Dec; 18(47):6996-7002. PubMed ID: 23322999
[TBL] [Abstract][Full Text] [Related]
18. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
[No Abstract] [Full Text] [Related]
19. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
